Patients first,
Faster access,
Healthier lives
Global Regulatory Partners Japan (GRP Japan) is a pharmaceutical company helping international life science companies bring products to Japanese patients quickly and safely.
About Us
GRP Japan is a pharmaceutical company helping to bring international medical solutions to Japanese patients quickly and safely. Many medical treatments and drugs available overseas take time to reach patients in Japan.
Our Japan expertise and global network make GRP Japan the vital link between international innovation and local patient care. We’re committed to ensuring patients and medical professionals across Japan have access to the treatments and solutions that improve lives.
For companies seeking to bring healthcare solutions into Japan or other countries, see our Industry Solutions.
Our Products
At GRP Japan, our product portfolio centers on areas where new solutions can make the greatest impact:
• Innovative medicines
• Diabetes
• Biosimilars
• High-risk medical products
By focusing on these therapeutic areas, we help ensure Japanese patients gain timely access to breakthrough therapies and technologies from around the world.
Product Lineup
Baqsimi Nasal Powder
Latest News
Baqsimi® Nasal Powder Featured in the September 2026 Issue of Nikkei DI
Global Regulatory Partners GK (GRP Japan) is pleased to share that Baqsimi® Nasal Powder, for which GRP Japan serves as the Marketing Authorization Holder (MAH) in Japan, is featured in the September 2026 issue of Nikkei Drug Information (Nikkei DI). Nikkei DI is a professional publication for pharmacists and other healthcare professionals in Japan, providing information on pharmaceuticals, clinical practice, medication management and developments relevant to pharmacy practice.GRP JAPAN JOINS THE JAPAN RADIOPHARMACEUTICALS ASSOCIATION
Tokyo, Japan — October 2026 — Global Regulatory Partners Japan (GRP Japan) is pleased to announce that it has joined the Japan Radiopharmaceuticals Association, effective October 2026. The membership marks an important step in GRP Japan’s continued expansion into the radiopharmaceutical and nuclear medicine sector, complementing the company’s established capabilities in pharmaceuticals, biologics, medical devices, and diagnostics. As a Marketing Authorization Holder (MAH) and local regulatory partner for international healthcare companies entering Japan, GRP Japan is expanding its capabilities to support the specialized regulatory, quality, importation, supply-chain, and lifecycle requirements associated with radiopharmaceutical products. Through its membership, GRP Japan looks forward to industry collaboration and to contributing its regulatory and market-access experience to the continued development of the sector in Japan.Global Regulatory Partners to Exhibit at BioJapan 2026
Global Regulatory Partners (GRP) is pleased to announce its participation in BioJapan 2026, where GRP will exhibit at Booth C-41 and participate in the event's international Partnering program. BioJapan 2026 is observing its 40th anniversary as the world’s longest running biotechnology event. It is held together with concurrent events,Regenerative Medicine JAPAN, and healthTECH JAPAN, bringing together biotechnology, pharmaceuticals, regenerative medicine, digital health, academia, investors, service providers, and other life-science stakeholders from Japan and around the world.Global Regulatory Partners Announces MHLW Approval of Pegfilgrastim Biosimilar in Japan
Tokyo, Japan – August 25, 2026 – Global Regulatory Partners GK (GRP GK) announced today that Japan's Ministry of Health, Labour and Welfare (MHLW) granted marketing approval on August 24, 2026, for Pegfilgrastim BS Subcutaneous Injection 3.6 mg 「GRP」, a pegfilgrastim biosimilar indicated for the prevention of febrile neutropenia associated with cancer chemotherapy.SEE ALL
